Tesla's Robotaxi service expands to another US city with major operational changes: 'Super attractive'
The new service covers a large area, from north of San Francisco down past San Jose, giving more people the chance to hop into a Model Y after the service's launch in Austin, Texas.
For riders, this means more convenient transportation in the busy region around San Francisco. Tesla CEO Elon Musk has also indicated the service could be cheaper than a bus ticket.
Unlike Austin's Robotaxis, which have a safety monitor in the passenger's seat, the Bay Area Robotaxis have a human driver supervising Tesla's Full Self-Driving system, ready to take control if needed.
So, while the San Francisco Robotaxis are not fully autonomous yet, like competitor Waymo, it's a step forward in what Tesla believes is a cleaner option for shared transportation.
From an environmental perspective, Tesla's Robotaxis could help reduce emissions by replacing gas-powered rides and encouraging more shared trips.
This expansion comes during a tough sales year for Tesla. In 2025, the company's vehicle deliveries have slowed due to increased competition and supply chain challenges, highlighting the hurdles Tesla faces even as it pushes new technologies.
Musk's previous involvement with the Trump administration has also caused some consumers to rethink their loyalty to the brand, even though the overall EV market continues to prove its staying power.
If you're considering an EV, installing solar panels can dramatically boost your overall savings associated with driving an electric vehicle. That's because charging your car with solar energy is much cheaper than using public charging or the grid.
EnergySage makes it easy to compare quotes from trusted local installers and can help you save up to $10,000 on solar installations.
Commenters seem to be intrigued by this development in the Bay Area, even though the Robotaxi launch in Austin resulted in some concerning footage of autonomous flubs making the rounds on the internet.
One commenter wrote, "Getting rides from Uber or Lyft from SF to San Jose is super painful. This makes that super attractive."
Another praised Tesla's progress, saying, "Slowly, but surely, and safely."
Would you be more likely to use a rideshare service that offers EV rides?
Absolutely
Only if it wasn't more expensive
Only if the wait times weren't longer
Not interested
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Elon Musk may be banking on his UK energy plan to boost Tesla's fortunes
Tesla's (TSLA) recent announcement that the company had applied to the regulator Ofgem revealed how keen Elon Musk is to shake up the UK energy market. The EV maker's bid to power UK homes and businesses is not a complete surprise, given that the company has been active in the energy space for a while, albeit in Texas and Australia. Its dedicated division, Tesla Energy, launched in 2006 and has developed battery and solar energy products, among others, with varying degrees of success. Tesla's Megapack and Powerwall energy storage systems are among the more notable products but revenues in the energy division have fallen year-on-year, company filings show. Read more: How Tesla's Cybertruck could keep UK homes running for days Still, it's clear Musk wants a piece of the UK energy market and is hoping it could help Tesla's fortunes. Tesla did not respond to a request for comment from Yahoo Finance UK. Problems have piled up for the EV maker over the past year, from slumping vehicle sales to a fall in operating income. Musk's work for Donald Trump's administration, specifically the Department of Government Efficiency (DOGE) team, led to a bitter fallout with the US president and speculation that Tesla investors were unhappy with his foray into politics. Seeking to reassure investors that Tesla (TSLA) was his priority, Musk said in a second-quarter conference call that there were a "few rough quarters ahead" but the long-term outcome for the company was "very high". One potential bright spot is the $16.5bn (£12.3bn) chip deal that Musk said Tesla (TSLA) had signed with Samsung ( Tesla's UK energy plan may be less high-profile than some of Musk's other ventures, illustrated in the chart below, but if it manages to solve distribution problems within a constrained network, the move could prove a winning strategy. Scott Flavell, head of energy for global consultancy firm Sia, told Yahoo Finance UK: "Tesla's planned UK energy market entry, via Tesla Energy Ventures, is less about selling household Powerwalls and more about cementing a position in large-scale energy storage and grid flexibility. "Already a global leader in utility-scale batteries, Tesla sees an opportunity in the UK's constrained energy network, where bottlenecks in transmission are slowing the delivery of renewable generation to demand centres." Flavell added: "By combining its Megapack infrastructure with targeted renewable generation, such as large-scale solar in less-constrained areas, Tesla can store surplus energy during low-demand periods and release it when the market pays a premium. The retail electricity offer, while grabbing headlines, serves as a customer acquisition layer and a source of aggregated flexibility to feed into this bigger play." There are no guarantees that Ofgem will approve the application but if the plan does succeed, Tesla could gain the power-up it needs by becoming a big player in the UK energy market. Read more: Should CEO pay be capped? Have your say UK economic growth slows between April and June Why Apple, Amazon and other tech giants are considering bitcoin Download the Yahoo Finance app, available for Apple and Android. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
South Africa Pushes Rule Review That Would Ease Starlink Entry
South Africa is prioritizing a policy-review process that may result in Elon Musk's SpaceX and other satellite-internet companies being allowed to operate in Africa's largest economy without ceding ownership, the nation's telecoms minister said. The Department of Communications and Digital Technologies is assessing 19,000 public submissions on a proposal to amend the nation's Black-economic empowerment regulations. The aim is to determine whether info-tech companies can operate in the country using equity-equivalent programs, instead of a 30% Black-ownership requirement.
Business Insider
an hour ago
- Business Insider
Why Pfizer's (PFE) Oncology Gamble is Finally Paying Off
Pfizer (PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported breakthrough survival data in muscle-invasive bladder cancer (MIBC) from the Phase 2 EV-303/KEYNOTE-905 trial—an encouraging validation of its oncology investments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That said, Pfizer still faces a difficult road ahead, with lingering post-pandemic uncertainty and looming patent expirations on major blockbusters like ELIQUIS and IBRANCE. Even so, the promising bladder cancer results, coupled with the stock's conservative valuation, attractive dividend yield, and approach toward a key resistance level, create an appealing setup. For these reasons, I remain cautiously Bullish as we near the three-quarter mark for the year. Facing a Massive Revenue Cliff Pfizer has become a prime example of the post-pandemic hangover in the stock market—similar to how Zoom (ZM), once synonymous with 'meetings,' has yet to regain its former glory. Pfizer's windfall came through its COVID products, COMIRNATY and PAXLOVID, which generated more than $55 billion in 2022. But with demand for both collapsing, the company now faces a massive revenue gap and an urgent question about its next growth engine. Adding to the pressure, Pfizer is staring down patent expirations on blockbuster drugs like ELIQUIS, IBRANCE, and XTANDI, putting billions in annual sales at risk. Still, it's not all doom and gloom. Pfizer remains profitable and continues to channel significant resources into R&D—investments aimed at fueling the next wave of blockbuster therapies. Like many of its peers, Pfizer has turned to acquisitions to strengthen its pipeline—with the $43 billion Seagen deal standing out as its most significant recent bet on oncology. A Pivotal Win Validates a Pricey Bet Which brings us to the present. Pfizer recently unveiled Phase 3 results for PADCEV (enfortumab vedotin), its antibody-drug conjugate acquired through Seagen, in combination with Merck's (MRK) KEYTRUDA. The regimen achieved the trial's primary endpoints, showing statistically significant improvements in both event-free survival (EFS) and overall survival (OS) among patients with muscle-invasive bladder cancer (MIBC) who were ineligible for cisplatin. Cisplatin remains a standard first-line therapy in MIBC, but its toxicity restricts use to patients who meet strict eligibility criteria. Roughly half of all MIBC patients do not qualify, leaving them with limited treatment options. With these results, PADCEV—Pfizer's prized Seagen asset—paired with KEYTRUDA is now positioned to emerge as a first-line therapy for thousands of cisplatin-ineligible MIBC patients. The Numbers Behind the Narrative In Pfizer's latest earnings report, the Oncology segment stood out, with sales climbing 11% to $4.39 billion. PADCEV, already FDA-approved for urothelial cancer, delivered powerful momentum—up 38% year-over-year to $542 million. This kind of growth is exactly what investors want to see as Pfizer leans deeper into oncology. A 38% surge ahead of a potential label expansion from the new MIBC data underscores PADCEV's blockbuster potential. On the flip side, an 8% YoY decline in IBRANCE sales (down to $1.05 billion) highlights why the MIBC data is so critical to Pfizer's future growth trajectory. PFE Stock Stands at a Technical Crossroads From a technical perspective, Pfizer's stock (weekly candles) is nearing its 50-day moving average—a level that has consistently acted as resistance since the pandemic. If PFE can break above its 50-day moving average and establish support, the stock could be setting up for brighter days ahead—particularly if fundamentals such as trial data and earnings continue to improve. In the meantime, investors still have reasons to stay interested: a hefty 6.8% dividend yield and a stock trading at a conservative valuation. At just 13.4x earnings—nearly a 50% discount to the Health Care sector average—much of the downside risk already appears baked into the price. Don't Ignore the Headwinds On the other hand, several headwinds could weigh on Pfizer's stock. Chief among them is the looming patent cliff between 2026 and 2028, which will demand outsized growth from its newer portfolio to offset. In addition, while Pfizer's Oncology segment has shown promising momentum, it operates in a fiercely competitive landscape with heavyweight rivals like Bristol-Myers Squibb (BMY) and Roche (RHHBY). Emerging next-generation therapies could also challenge the PADCEV/KEYTRUDA combo in MIBC, underscoring the risks ahead. Is Pfizer a Buy, Hold, or Sell? On Wall Street, PFE earns a Moderate Buy consensus rating based on six Buy, 12 Hold, and zero Sell ratings in the past three months. PFE's average stock price target of $28.50 implies an upside potential of 13.7% over the next twelve months. Pfizer's Oncology Bet Needs Time to Prosper In conclusion, Pfizer's oncology strategy is starting to deliver results at a pivotal moment. For the past two years, the company has been defined by cost-cutting and strategic repositioning amid a steep post-COVID revenue drop and looming patent cliffs. Now, the breakthrough survival data from the PADCEV/KEYTRUDA combo in bladder cancer provides meaningful validation of its turnaround efforts. Expanding PADCEV into indications like MIBC is essential to offset expected losses from blockbusters such as ELIQUIS and IBRANCE. Most importantly, Pfizer is executing on its oncology roadmap—a cornerstone for future growth. This progress has the potential to rekindle broader investor interest beyond its 'value' and 'dividend' profile, leaving me cautiously bullish despite the risks.
